|1.||Lubet, Ronald A: 3 articles (11/2013 - 04/2008)|
|2.||Lubet, R A: 3 articles (12/2001 - 03/2000)|
|3.||You, Ming: 2 articles (11/2013 - 01/2013)|
|4.||Grubbs, Clinton J: 2 articles (11/2013 - 04/2008)|
|5.||Bode, Ann M: 2 articles (11/2013 - 04/2008)|
|6.||You, M: 2 articles (11/2001 - 08/2000)|
|7.||Grubbs, C J: 2 articles (11/2001 - 03/2000)|
|8.||Hu, L: 2 articles (11/2001 - 08/2000)|
|9.||Goss, P E: 2 articles (02/2001 - 11/2000)|
|10.||Strasser, K: 2 articles (02/2001 - 11/2000)|
|1.||Breast Neoplasms (Breast Cancer)
09/01/1997 - "Phase II clinical studies found vorozole to be an effective agent for the treatment of postmenopausal women with advanced breast cancer, achieving objective responses in up to 35% of patients. "
03/01/1995 - "Vorozole, given orally, is a clinically active well-tolerated new treatment for breast cancer. "
06/01/1998 - "Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group)."
01/01/1998 - "Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients."
08/01/1997 - "Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. "
02/15/2002 - "In the vorozole group, the correlations of proportional changes in Ki67 at 2 weeks with tumor volume changes and clinical response at 12 weeks were not significant (P =.09) and marginally significant (P =.04), respectively. "
08/01/1998 - "Although this intermittent treatment did inhibit the appearance of new tumors during each of the periods that vorozole was administered, it did not cause regression of palpable cancers."
08/01/1998 - "Treatment of rats with vorozole for limited time periods, from 3 days post-MNU administration until 30 or 60 days post-MNU treatment, resulted in significant delays in the time to appearance of palpable cancers. "
08/01/1998 - "Even the two lowest doses of vorozole (0.16 and 0.08 mg/kg body wt/ day) decreased cancer multiplicity -50%. "
08/01/1998 - "The next two highest doses of vorozole (0.63 and 0.31 mg/kg body wt/day) inhibited MNU-induced mammary cancer multiplicity by 70-80%. "
12/01/2001 - "These data, which are considered hypothesis generating, provide evidence that low doses of vorozole in the diet select for mammary carcinomas with an increased ER positive phenotype."
12/01/2001 - "All carcinomas from vorozole-treated rats expressed PR (2.5-60.2%) and correlation between ER and PR content was numerically greater in carcinomas from vorozole-treated animals (r = 0.42, p = 0.09). "
12/01/2001 - "In vorozole-treated rats, no ER negative carcinomas were observed and overall ER expression by vorozole was elevated (p < 0.03). "
03/01/2000 - "Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole."
03/01/1993 - "In the DMBA-induced rat mammary carcinoma model, vorozole at an oral dose of 2.5 mg/kg b.i.d. "
|4.||Body Weight (Weight, Body)
12/01/1994 - "This chemopreventive effect was accompanied by significant increases in body weight gain in the animals treated with vorozole when compared with control rats. "
12/01/2001 - "injection of 50mg MNU/kg body weight at 21 days of age and placed on diet supplemented with 0 or 3 mg vorozole/kg, which had no effect on mammary tumor development. "
|9.||Megestrol Acetate (Borea)